Incidence of hearing loss 4 weeks after last dose of cisplatin [clinicaltrials_resource:e90a4c166fbfd4b088fdead2be255a05]
Hearing loss is defined by comparing hearing sensitivity at follow up evaluation (4 weeks following the last dose of cisplatin) relative to baseline measurements using ASHA criteria. The proportion of patients treated with sodium thiosulfate who develop hearing loss will be compared with that of patients who did not receive the study drug.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Incidence of hearing loss 4 weeks after last dose of cisplatin [clinicaltrials_resource:e90a4c166fbfd4b088fdead2be255a05]
Hearing loss is defined by comparing hearing sensitivity at follow up evaluation (4 weeks following the last dose of cisplatin) relative to baseline measurements using ASHA criteria. The proportion of patients treated with sodium thiosulfate who develop hearing loss will be compared with that of patients who did not receive the study drug.
Bio2RDF identifier
e90a4c166fbfd4b088fdead2be255a05
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e90a4c166fbfd4b088fdead2be255a05
measure [clinicaltrials_vocabulary:measure]
Incidence of hearing loss
time frame [clinicaltrials_vocabulary:time-frame]
4 weeks after last dose of cisplatin
description
Hearing loss is defined by com ...... id not receive the study drug.
identifier
clinicaltrials_resource:e90a4c166fbfd4b088fdead2be255a05
title
Incidence of hearing loss 4 weeks after last dose of cisplatin
@en
type
label
Incidence of hearing loss 4 we ...... a4c166fbfd4b088fdead2be255a05]
@en